Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Have you been on the pop today watching?
Wynbore. I wonder which part of the world you are from
I would what country operates from ?
11) the three amigos continue to relentlessly post fud, mostly made up... Twats....
What do we know so far:
1) Its all about AVA6000 (and perhaps Affyxcel)
MOSTLY......
2) The Initial Phase 1 trial (3 weekly dosing) overran terribly and the dosing interval appears to have been sub-optimal.
YOUR ASSUMPTION ABOUT SUB OPTIMAL MAKING UP YOUR OWN NARRATIVE....
3) They changed mid-trial to have a 2 weekly dosing arm and at this stage the Chief Development Officer (Neil Bell) left without explanation. Culpable or disagreed?
AGAIN YOUR ASSUMPTION OF WHAT YOU THINK. THE ACTUAL Trial WAS WORKING BETTER THAN EXPECTED SO MOVED TO 2 WEEK DOSING. I SEE THAT AS GOOD.
DR BELL WAS A CONSULTANT ANT THEY ALL MOVE ON
---MY ASSUMPTION AND OPINION
4) They sorted ongoing funding via an increasingly onerous Heights Loan Noted deal.
AGREE AT THE TIME LOOKED GOOD BUT WITH HINDISGHT NOT A GOOD MOVE.
CANNOT REMEMBER YOU OR YOUR ALTER EGO SAYING IT WAS A BAD MOVE...
MY OPINION.
5) True to form the 2 weekly trial is already missing deadlines.
YOU HAVE A BEE IN YOUR BONNET ABOUT THIS BUT IT IS A GAME CHANGER AND OBS YOU ARE THICK AS MINCE.
EVEN AVACTA CANNOT DICTATE WHAT PATIENTS ON ANY TRIAL MAY OR MAY NOT DO OR REACT AND HAVE OTHER REASONS. THIS IS A REAL LIFE TRIAL AND LOKE ALL OTHER TRIALS IS PRONE TO TIMELINE ISSUES GIVEN WHO AND WHAT AVACTA ARE DOING.
6) The recent Fund Raise was far from a success. A small amount that wasn't enough to clear the Heights funding not fund AVA6000 through to completion, indeed only 'into' Phase 2.
STATING WHAT NEARLY ALL OF US AGREE WITH. SO DITTO
7) As Wyn says the size of the raise and the heavy discount is not indicative of compelling data at this point, or possibly at any time in the near future?
NO PROOF TO THAT CONCLUSION. I COULD ALSO THROW ONE IN BASED AROUND CORRUPTION AND DEUTCHE BANK EMPLOYEES OR SIMILAR SHORTERS THAT ARE ON A MISSION TO DEPRESS THE SP WHICH THEY HAVE ATTACKED NOW FOR NEARLY 2 YEARS
8) And then the CEO was forced out and a relatively new employee was 'fast tracked' into the post. No one else interested?
EVERYONE HAS AN OPINION ON THIS. READ BETWEEN THE LINES AND IT IS Obvious THAT IS POTENTIALLY ONLY CC IS INTERIM.
THEY HAVE CONCLUDED THE TEAM NEEDS BOLSTERING WITH PERSONNEL WHO WILL DRIVE THE PRODUCT TO MARKET AND THEOUGH THE TRIAL TO DEALS THAT ARE ALREADY BEING DISCUSSED.
9) Why no LG update? If they're still working on this then we should be told. Worryingly the RNS page is littered with historic RNSs of deals made than then are simply never mentioned again. Is LG about to join this group too?
IT IS ONGOING. IF THEY ARE STILL WORKING ON THIS THEN WHY UPDATE UNTIL THEY HAVE NEWS
10) Likewise Affimers and antibody mimetics, 'drugable pockets' etc etc. All the other things that we might be doing but don't appear to be. Where's the information?
IM SURE AFFIMERS HAVE BEEN COMMUNICATED IN RECENT RNSs...But you assume yet again your own narrative.
You see an SP which is at a low. It has been attacked TW factual proof and now some
Off you trot.🤡
“If the strategy is changing, the board should
be changed. If the board is functioning
properly, it should recognise that new skills
should be brought on to accommodate this.”
And AS should have known this as CEO and not been surprised.
Thanks GMCC, for your help and all your research.
Https://www.criticaleye.com/inspiring/insights-servfile.cfm?id=2239
People at that level are frequent-flyer members.
Hi Thompi I had the same issue , this link helps how to do it . Yes think they will looking to licence out to numerous partners .Think stem cells technology very exciting looks like using affimers is the easy bit .
https://www.bing.com/videos/riverview/relatedvideo?q=you+tube+change+subtitles+to+english+video&mid=88F3E78863012EDF5FFB88F3E78863012EDF5FFB&FORM=VIRE
Thanks GMCC for the presentation link. I couldn’t get the subtitles/transcript to work in English, but I took a screenshot of the final slide and ran it through a couple of translation Apps. It may not be perfect, but the two translations were pretty identical.
Did you get under No.2 on the slide that there is a big pharma contract in progress? And also something about a spin-out under No.5?
I said bed sit ! Dosent AI. Understand that word. Once a clown all was a clown. You fool
B2, CC would’ve been given the role because she presented the best proposed strategy and credentials. She will hopefully configure the team to deliver her vision.
She seems to have a good blend of managerial experience and science credentials with industry contacts.
We need evolution not revolution.
Thornogson may I suggest selling up and leaving us all in peace. Oh and as for terribly overrun does the fact that they only expected to do 4 cohorts and ended on the 7th with no MTD and the change to 2 weekly dosing was because the Safety data was so good that they could pump the red devil in a little more often to see if it benefitted the patients further. Don't forget to sell up first thing
It's all about pre | CISION™
What do we know so far:
1) Its all about AVA6000 (and perhaps Affyxcel)
2) The Initial Phase 1 trial (3 weekly dosing) overran terribly and the dosing interval appears to have been sub-optimal.
3) They changed mid-trial to have a 2 weekly dosing arm and at this stage the Chief Development Officer (Neil Bell) left without explanation. Culpable or disagreed?
4) They sorted ongoing funding via an increasingly onerous Heights Loan Noted deal.
5) True to form the 2 weekly trial is already missing deadlines.
6) The recent Fund Raise was far from a success. A small amount that wasn't enough to clear the Heights funding not fund AVA6000 through to completion, indeed only 'into' Phase 2.
7) As Wyn says the size of the raise and the heavy discount is not indicative of compelling data at this point, or possibly at any time in the near future?
8) And then the CEO was forced out and a relatively new employee was 'fast tracked' into the post. No one else interested?
9) Why no LG update? If they're still working on this then we should be told. Worryingly the RNS page is littered with historic RNSs of deals made than then are simply never mentioned again. Is LG about to join this group too?
10) Likewise Affimers and antibody mimetics, 'drugable pockets' etc etc. All the other things that we might be doing but don't appear to be. Where's the information?
Silence only allows people to suspect the worst. If any of the above is happening and going well then why not tell the World? Generate a buzz and some word of mouth excitement.
Rerate 40p ????
All sounds very positive.
Rerate incoming as soon as they're signed up to the citizens.
Bella ---
I might be mistaken but am sure I recall someone on here saying CC would be based here in the UK?
Perhaps someone on Twitter/X may wish to ask CC to confirm what her location situation is but I suspect it will remain a secret.
Given that there may well be advantages with her either being in the UK or the States it's difficult to know which would be the most favoured.
A Man City player lives near to me and we say hello when we walk our dogs.
Do you think I'll get a start on SaturdayTouk?
🤡. Working overtime on bank holiday Get out side for gods sake !
It’s beautiful day !
Sitting in your bed sit typing away. Is dead weird!
We Are Groot -
"the evolution of the board. There are some critical competencies here that we know are needed, and this is ongoing, has been ongoing in parallel with the CEO search."
If there is to be strategy reform as you mentioned, it would need to be done with the new BoD in place,
as it doesn't make sense for that to happen before.
Thompi,
I think this whole area of coms and the lack and poorness of it, is hugely misplaced here on this BB.
There is (relatively) nothing to communicate about. That's the point.
Realistically, if the company had great news to sing from the rooftops they would. They are not stupid, and I mean that.
Any company with a developing tech with good, positive or in AVCT's case, potentially groundbreaking, info would be releasing that data and publishing it non-stop.
It highlights the company potentially bringing it into the view of bigger partners/ or takeover offers beyond the usual suspects. It would make itself known to the wider market allowing funds that perhaps would not immediately look at this type of company to run the rule over it as well as perhaps attracting bigger PI's to build a small stake too, all of which bolsters the SP and increases the chance of better funding terms as and when necessary.
Yet this has never happened, even though they have changed companies to do this. Why is that?
I saw that with the covid raise. Yes, in hindsight it was a bit of a bandwagon exercise, but at the time loads of "investors" saw the potential returns on this novel approach and piled in based on what AVCT said.
There is a reason why the AVCT sp is where it is. There is a reason the science day flopped, there is a reason why the last but one raise was 95p and now this one at 50p.
The coms is not the issue.
I don't pretend to understand the science. (Yes I can keep up with the general thrust of what is being attempted as we all can), but to me it is obvious that the people who can break this down are seeing something else too.
Either its a long way to go with a lot more data needed to substantiate the first promising but tiny data trials to date, or it does not "work" as effectively as we hoped?
I don't know and neither do any of us here. but I tell you this for nothing, the SP always tells the story.
No "successful" company has a SP in this sort of long term downtrend.
This is not to say it won't get turned around and if it does the low at 40p will in hindsight, tell the story of all the failure of the covid tech, the delays and the extensions and the change in strategy and the sacking of Board members, the continuing dilution of RI's before it took off when new data arrived.
Whether it does take off or continues to decline none of us knows, but when we look back it will blindingly obvious how the SP reflected the story, with whatever outcome results.
To think we can predict any of this is always a case of Hubris, imo.
As I’ve said many times before, CC has friends at Novartis and they are neighbours with Avacta on White City. 👍